Apolipoprotein E (APOE) Peptide
APOE
Reactivité: Humain
Hôte: Synthetic
BP, IHC, WB
N° du produit ABIN973323
Aperçu rapide pour Apolipoprotein E (APOE) Peptide (ABIN973323)
Antigène
APOE
(Apolipoprotein E (APOE))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
-
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-APOE antibody (Catalog #: ARP54283_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
Apolipoprotein E (APOE) peptide
APOE Reactivité: Humain Hôte: Synthetic BP, Imm
-
-
Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- APOE (Apolipoprotein E (APOE))
-
Sujet
-
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: AD2, MGC1571, apoprotein, LPG, LDLCQ5
Protein Interaction Partner: CNTF,CNTF,HCVgp1,A2M,ALB,APOE,APP,CNTF,CTSB,LDLR,LRP1,LRP2,LRP8,MAP2,MAPT,NEFM,PLTP,PRNP,SCARB1,VLDLR,A2M,LRP2,LRP8,MAPT,NEFM,PLTP
Protein Size: 317 -
Poids moléculaire
- 34 kDa
-
ID gène
- 348
-
NCBI Accession
- NM_000041, NP_000032
-
UniProt
- P02649
Antigène
-
Vous êtes ici:
